Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Current Oncology Reports
Erschienen in: Current Oncology Reports 9/2022

11.04.2022 | Anesthesiology and Critical Care (JP Cata, Section Editor)

Enhanced Recovery After Surgery (ERAS) in Surgical Oncology

verfasst von: Javier Ripollés-Melchor, Ane Abad-Motos, Andrés Zorrilla-Vaca

Erschienen in: Current Oncology Reports | Ausgabe 9/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose of the Review

The objective of this review is to address the rationale behind the application of the Enhanced Recovery After Surgery (ERAS) protocols that could improve oncologic outcomes in adult patients undergoing major surgery.

Recent Findings

The implementation of ERAS protocols has been associated with fewer postoperative complications as well as decreased return to intended oncologic treatment (RIOT). However, few studies have analyzed the influence of the application of ERAS protocols and long-term oncologic outcomes, although some of its individual elements have been associated with improvements in oncologic outcomes, including overall survival and disease-free survival.

Summary

Targeted long-term follow-up studies in specific oncologic procedures are required to determine whether ERAS application results in improved oncologic outcomes.
Literatur
1.
Kehlet H. Enhanced Recovery After Surgery (ERAS): good for now, but what about the future? Can J Anaesth. 2015;62:99–104.PubMedCrossRef
2.
Kehlet H, Mogensen T. Hospital stay of 2 days after open sigmoidectomy with a multimodal rehabilitation programme. Br J Surg. 1999;86:227–30.PubMedCrossRef
3.
Ljungqvist O, Scott M, Fearon KC. Enhanced recovery after surgery: a review. JAMA Surg. 2017;152:292–8.PubMedCrossRef
4.
Singh SM, Liverpool A, Romeiser JL, Thacker J, Gan TJ, Bennett-Guerrero E. Types of surgical patients enrolled in enhanced recovery after surgery (ERAS) programs in the USA. Perioper Med (London, England). 2021;10:12.CrossRef
5.
•• Lee Y, Yu J, Doumouras AG, Li J, Hong D. Enhanced recovery after surgery (ERAS) versus standard recovery for elective gastric cancer surgery: a meta-analysis of randomized controlled trials. Surg Oncol. 2020;32:75–87. This meta-analysis, which included 14 studies, showed that the application of ERAS in gastric cancer can reduce length of stay, costs and time to return to function after gastric cancer surgery compared to conventional recovery. However, ERAS may increase the number of postoperative readmissions, although with no impact on the rate of postoperative complications, and there was no analysis of oncologic outcomes.PubMedCrossRef
6.
Bisch SP, Jago CA, Kalogera E, Ganshorn H, Meyer LA, Ramirez PT, et al. Outcomes of enhanced recovery after surgery (ERAS) in gynecologic oncology - a systematic review and meta-analysis. Gynecol Oncol. 2021;161:46–55.PubMedCrossRef
7.
Ni X, Jia D, Chen Y, Wang L, Suo J. Is the Enhanced Recovery After Surgery (ERAS) program effective and safe in laparoscopic colorectal cancer surgery? A Meta-analysis of randomized controlled trials. J Gastrointest Surg. 2019;23:1502–12.PubMedCrossRef
8.
Oh C, Moriarty J, Borah BJ, Mara KC, Harmsen WS, Saint-Cyr M, et al. Cost analysis of enhanced recovery after surgery in microvascular breast reconstruction. J Plast Reconstr Aesthet Surg. 2018;71:819–26.PubMedCrossRef
9.
Tejedor P, Pastor C, Gonzalez-Ayora S, Ortega-Lopez M, Guadalajara H, Garcia-Olmo D. Short-term outcomes and benefits of ERAS program in elderly patients undergoing colorectal surgery: a case-matched study compared to conventional care. Int J Colorectal Dis. 2018;33:1251–8.PubMedCrossRef
10.
Miralpeix E, Nick AM, Meyer LA, Cata J, Lasala J, Mena GE, et al. A call for new standard of care in perioperative gynecologic oncology practice: impact of enhanced recovery after surgery (ERAS) programs. Gynecol Oncol. 2016;141:371–8.PubMedPubMedCentralCrossRef
11.
Hiller JG, Perry NJ, Poulogiannis G, Riedel B, Sloan EK. Perioperative events influence cancer recurrence risk after surgery. Nat Rev Clin Oncol. 2018;15:205–18.PubMedCrossRef
12.
Margraf A, Ludwig N, Zarbock A, Rossaint J. Systemic inflammatory response syndrome after surgery: mechanisms and protection. Anesth Analg. 2020;131:1693–707.PubMedCrossRef
13.
Bassani B, Baci D, Gallazzi M, Poggi A, Bruno A, Mortara L. Natural killer cells as key players of tumor progression and angiogenesis: old and novel tools to divert their pro-tumor activities into potent anti-tumor effects. Cancers (Basel). 2019;11(4):461.
14.
Thomas M. Advances in oncoanaesthesia and cancer pain. Cancer Treat Res Commun. 2021;29:100491.PubMedCrossRef
15.
Pędziwiatr M, Mavrikis J, Witowski J, Adamos A, Major P, Nowakowski M, et al. Current status of enhanced recovery after surgery (ERAS) protocol in gastrointestinal surgery. Med Oncol. 2018;35:95.PubMedPubMedCentralCrossRef
16.
Manso M, Schmelz J, Aloia T. ERAS-Anticipated outcomes and realistic goals. J Surg Oncol. 2017;116:570–7.PubMedCrossRef
17.
Biagi JJ, Raphael MJ, Mackillop WJ, Kong W, King WD, Booth CM. Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer: a systematic review and meta-analysis. JAMA. 2011;305:2335–42.PubMedCrossRef
18.
Hofstetter G, Concin N, Braicu I, Chekerov R, Sehouli J, Cadron I, et al. The time interval from surgery to start of chemotherapy significantly impacts prognosis in patients with advanced serous ovarian carcinoma - analysis of patient data in the prospective OVCAD study. Gynecol Oncol. 2013;131:15–20.PubMedCrossRef
19.
Kim BJ, Caudle AS, Gottumukkala V, Aloia TA. The impact of postoperative complications on a timely return to intended oncologic therapy (RIOT): the role of enhanced recovery in the cancer journey. Int Anesthesiol Clin. 2016;54:e33-46.PubMedCrossRef
20.
Tankou JI, Foley O, Falzone M, Kalyanaraman R, Elias KM. Enhanced recovery after surgery protocols improve time to return to intended oncology treatment following interval cytoreductive surgery for advanced gynecologic cancers. Int J Gynecol Cancer. 2021;31:1145–53.PubMedCrossRef
21.
Nelson DB, Mehran RJ, Mitchell KG, Correa AM, Sepesi B, Antonoff MB, et al. Enhanced recovery after thoracic surgery is associated with improved adjuvant chemotherapy completion for non-small cell lung cancer. J Thorac Cardiovasc Surg. 2019;158:279-286.e1.PubMedCrossRef
22.
Slim K, Theissen A. Enhanced recovery after elective surgery. A revolution that reduces post-operative morbidity and mortality. J Visc Surg. 2020;157:487–91.PubMedCrossRef
23.
Hayden JM, Oras J, Block L, Thörn S-E, Palmqvist C, Salehi S, et al. Intraperitoneal ropivacaine reduces time interval to initiation of chemotherapy after surgery for advanced ovarian cancer: randomised controlled double-blind pilot study. Br J Anaesth. 2020;124:562–70.PubMedCrossRef
24.
• Ripollés-Melchor J, Ramírez-Rodríguez JM, Casans-Francés R, Aldecoa C, Abad-Motos A, Logroño-Egea M, et al. Association between use of enhanced recovery after surgery protocol and postoperative complications in colorectal surgery: the postoperative outcomes within enhanced recovery after surgery protocol (POWER) Study. JAMA Surg. 2019;154:725–36. This study included more than 2000 patients and showed that having a protocol alone does not improve short-term results, but is directly dependent on adherence to ERAS protocols.PubMedPubMedCentralCrossRef
25.
Ripollés-Melchor J, Abad-Motos A, Díez-Remesal Y, Aseguinolaza-Pagola M, Padin-Barreiro L, Sánchez-Martín R, et al. Association between use of enhanced recovery after surgery protocol and postoperative complications in total hip and knee arthroplasty in the postoperative outcomes within enhanced recovery after surgery protocol in elective total hip and knee arthroplast. JAMA Surg. 2020;12:e196024–e196024.CrossRef
26.
Khuri SF, Henderson WG, DePalma RG, Mosca C, Healey NA, Kumbhani DJ. Determinants of long-term survival after major surgery and the adverse effect of postoperative complications. Ann Surg. 2005;242:323–6.CrossRef
27.
Tjeertes EKM, Ultee KHJ, Stolker RJ, Verhagen HJM, Bastos Gonçalves FM, Hoofwijk AGM, et al. Perioperative complications are associated with adverse long-term prognosis and affect the cause of death after general surgery. World J Surg [Internet]. 2016;40:2581–90.CrossRef
28.
Tevis SE, Kohlnhofer BM, Stringfield S, Foley EF, Harms BA, Heise CP, et al. Postoperative complications in patients with rectal cancer are associated with delays in chemotherapy that lead to worse disease-free and overall survival. Dis Colon Rectum. 2013;56:1339–48.PubMedCrossRef
29.
Chau I, Norman AR, Cunningham D, Tait D, Ross PJ, Iveson T, et al. A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer. Ann Oncol Off J Eur Soc Med Oncol. 2005;16:549–57.CrossRef
30.
Aoyama T, Oba K, Honda M, Sadahiro S, Hamada C, Mayanagi S, et al. Impact of postoperative complications on the colorectal cancer survival and recurrence: analyses of pooled individual patients’ data from three large phase III randomized trials. Cancer Med. 2017;6:1573–80.PubMedPubMedCentralCrossRef
31.
Waldenstedt S, Bock D, Haglind E, Sjöberg B, Angenete E. Intraoperative adverse events as a risk factor for local recurrence of rectal cancer after resection surgery. Colorectal Dis. 2021. https://​doi.​org/​10.​1111/​codi.​16036. Epub ahead of print.
32.
Scott MJ, Baldini G, Fearon KCH, Feldheiser A, Feldman LS, Gan TJ, et al. Enhanced Recovery after Surgery (ERAS) for gastrointestinal surgery, part 1: Pathophysiological considerations. Acta Anaesthesiol Scand. 2015;59:1212–31.PubMedPubMedCentralCrossRef
33.
Mari G, Crippa J, Costanzi A, Mazzola M, Rossi M, Maggioni D. ERAS Protocol reduces IL-6 secretion in colorectal laparoscopic surgery: results from a randomized clinical trial. Surg Laparosc Endosc Percutan Tech. 2016;26:444–8.PubMedCrossRef
34.
Coffey JC, Wang JH, Smith MJF, Bouchier-Hayes D, Cotter TG, Redmond HP. Excisional surgery for cancer cure: therapy at a cost. Lancet Oncol. 2003;4:760–8.PubMedCrossRef
35.
Sammour T, Kahokehr A, Chan S, Booth RJ, Hill AG. The humoral response after laparoscopic versus open colorectal surgery: a meta-analysis. J Surg Res. 2010;164:28–37.PubMedCrossRef
36.
Camus Y, Delva E, Cohen S, Lienhart A. The effects of warming intravenous fluids on intraoperative hypothermia and postoperative shivering during prolonged abdominal surgery. Acta Anaesthesiol Scand. 1996;40:779–82.PubMedCrossRef
37.
Greisen J, Juhl CB, Grøfte T, Vilstrup H, Jensen TS, Schmitz O. Acute pain induces insulin resistance in humans. Anesthesiology. 2001;95:578–84.PubMedCrossRef
38.
Ljungqvist O. Modulating postoperative insulin resistance by preoperative carbohydrate loading. Best Pract Res Clin Anaesthesiol. 2009;23:401–9.PubMedCrossRef
39.
Yang D, He W, Zhang S, Chen H, Zhang C, He Y. Fast-track surgery improves postoperative clinical recovery and immunity after elective surgery for colorectal carcinoma: randomized controlled clinical trial. World J Surg. 2012;36:1874–80.PubMedPubMedCentralCrossRef
40.
Gustafsson UO, Oppelstrup H, Thorell A, Nygren J, Ljungqvist O. Adherence to the ERAS protocol is associated with 5-year survival after colorectal cancer surgery: a retrospective cohort study. World J Surg. 2016;40:1741–7.PubMedCrossRef
41.
•• Pisarska M, Torbicz G, Gajewska N, Rubinkiewicz M, Wierdak M, Major P, et al. Compliance with the ERAS protocol and 3-year survival after laparoscopic surgery for non-metastatic colorectal cancer. World J Surg. 2019;43:2552–60. This study demonstrated an association between ERAS protocol adherence and long-term survival after laparoscopic colorectal surgery for nonmetastatic cancer. Lower protocol adherence, regardless of cancer stage and postoperative complications, was an independent risk factor for worsened survival rates.PubMedCrossRef
42.
St-Amour P, St-Amour P, Joliat G-R, Eckert A, Labgaa I, Roulin D, et al. Impact of ERAS compliance on the delay between surgery and adjuvant chemotherapy in hepatobiliary and pancreatic malignancies. Langenbeck’s Arch Surg. 2020;405:959–66.CrossRef
43.
Ljungqvist O, Scott M, Fearon KC. Enhanced recovery after surgery a review. JAMA Surg. 2017;152:292–8.PubMedCrossRef
44.
Jayne DG, Guillou PJ, Thorpe H, Quirke P, Copeland J, Smith AMH, et al. Randomized trial of laparoscopic-assisted resection of colorectal carcinoma: 3-year results of the UK MRC CLASICC Trial Group. J Clin Oncol. 2007;25:3061–8.PubMedCrossRef
45.
Kuhry E, Schwenk WF, Gaupset R, Romild U, Bonjer HJ. Long-term results of laparoscopic colorectal cancer resection. Cochrane database Syst Rev. 2008;2008:CD003432.PubMedCentral
46.
Falcetta FS, Lawrie TA, Medeiros LR, da Rosa MI, Edelweiss MI, Stein AT, et al. Laparoscopy versus laparotomy for FIGO stage I ovarian cancer. Cochrane database Syst Rev. 2016;10:CD005344.PubMed
47.
Bonjer HJ, Deijen CL, Abis GA, Cuesta MA, van der Pas MHGM, de Lange-de Klerk ESM, et al. A randomized trial of laparoscopic versus open surgery for rectal cancer. N Engl J Med. 2015;372:1324–32.PubMedCrossRef
48.
Gustafsson UO, Scott MJ, Hubner M, Nygren J, Demartines N, Francis N, et al. Guidelines for perioperative care in elective colorectal surgery: Enhanced Recovery After Surgery (ERAS(®)) Society Recommendations: 2018. World J Surg. 2019;43:659–95.PubMedCrossRef
49.
Gupta D, Lis CG. Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiological literature. Nutr J. 2010;9:69.PubMedPubMedCentralCrossRef
50.
Carli F, Baldini G. From preoperative assessment to preoperative optimization of frail older patiens. Eur J Surg Oncol. 2021;47:519–23.PubMedCrossRef
51.
Carli F, Charlebois P, Baldini G, Cachero O, Stein B. An integrated multidisciplinary approach to implementation of a fast-track program for laparoscopic colorectal surgery. Can J Anaesth. 2009;56:837–42.PubMedCrossRef
52.
• Carli F, Bousquet-Dion G, Awasthi R, Elsherbini N, Liberman S, Boutros M, et al. Effect of multimodal prehabilitation vs postoperative rehabilitation on 30-day postoperative complications for frail patients undergoing resection of colorectal cancer: a randomized clinical trial. JAMA Surg. 2020;155:233–42. This study suggests that prehabilitation does not improve postoperative outcomes compared with postoperative rehabilitation in frail patients undergoing colorectal cancer resectionPubMedPubMedCentralCrossRef
53.
Barberan-Garcia A, Ubré M, Roca J, Lacy AM, Burgos F, Risco R, et al. Personalised prehabilitation in high-risk patients undergoing elective major abdominal surgery : a randomized blinded controlled trial. Ann Surg. 2018;267:50–6.PubMedCrossRef
54.
• Trépanier M, Minnella EM, Paradis T, Awasthi R, Kaneva P, Schwartzman K, et al. Improved disease-free survival after prehabilitation for colorectal cancer surgery. Ann Surg. 2019;270:493–501 Of importance This study demonstrated an association between prehabilitation and improved 5-year DFS in stage III colorectal cancer (73.4% vs 50.9%, P = 0.044).
55.
Hu WH, Cajas-Monson LC, Eisenstein S, Parry L, Cosman B, Ramamoorthy S. Preoperative malnutrition assessments as predictors of postoperative mortality and morbidity in colorectal cancer: an analysis of ACS-NSQIP. Nutr J. 2015;14:91.PubMedPubMedCentralCrossRef
56.
Song H-N, Wang W-B, Luo X, Huang D-D, Ruan X-J, Xing C-G, et al. Effect of GLIM-defined malnutrition on postoperative clinical outcomes in patients with colorectal cancer. Jpn J Clin Oncol. 2022;49:972–84.
57.
Gillis C, Buhler K, Bresee L, Carli F, Gramlich L, Culos-Reed N, et al. Effects of nutritional prehabilitation, with and without exercise, on outcomes of patients who undergo colorectal surgery: a systematic review and meta-analysis. Gastroenterology. 2018;155:391-410.e4.PubMedCrossRef
58.
McIsaac DI, Gill M, Boland L, Hutton B, Branje K, Shaw J, et al. Prehabilitation in adult patients undergoing surgery: an umbrella review of systematic reviews. Br J Anaesth. 2022;128:244–57.PubMedCrossRef
59.
Gillis C, Ljungqvist O, Carli F. Prehabilitation, enhanced recovery after surgery, or both? A narrative review. Br J Anaesth. 2022;128(3):434–48.
60.
Broggi MS, Oladeji PO, Tahmid S, Hernandez-Irizarry R, Allen J. Depressive disorders lead to increased complications after geriatric hip fractures. Geriatr Orthop Surg Rehabil. 2021;25(12):21514593211016252.
61.
AbuRuz ME, Al-Dweik G, Al-Akash HY. Checking the moderating effect of perceived control on the relationship between anxiety and postoperative hospital length of stay among coronary artery bypass graft patients. Int J Gen Med. 2019;12:79.PubMedPubMedCentralCrossRef
62.
Manou-Stathopoulou V, Korbonits M, Ackland GL. Redefining the perioperative stress response: a narrative review. Br J Anaesth. 2019;123:570–83.PubMedCrossRef
63.
•• Eckerling A, Ricon-Becker I, Sorski L, Sandbank E, Ben-Eliyahu S. Stress and cancer: mechanisms, significance and future directions. Nat Rev Cancer. 2021;21:767–85. This review describes the stress-mediated factors related to tumor growth identified by preclinical research and the parallel clinical findings.
64.
Tas F, Eralp Y, Basaran M, Sakar B, Alici S, Argon A, et al. Anemia in oncology practice: relation to diseases and their therapies. Am J Clin Oncol. 2002;25:371–9.PubMedCrossRef
65.
Liu X, Qiu H, Huang Y, Xu D, Li W, Li Y, et al. Impact of preoperative anemia on outcomes in patients undergoing curative resection for gastric cancer: a single-institution retrospective analysis of 2163 Chinese patients. Cancer Med. 2018;7:360–9.PubMedPubMedCentralCrossRef
66.
Walsh JC, Lebedev A, Aten E, Madsen K, Marciano L, Kolb HC. The clinical importance of assessing tumor hypoxia: relationship of tumor hypoxia to prognosis and therapeutic opportunities. Antioxid Redox Signal. 2014;21:1516–54.PubMedPubMedCentralCrossRef
67.
Vaupel P. The role of hypoxia-induced factors in tumor progression. Oncologist. 2004;9(Suppl 5):10–7.PubMedCrossRef
68.
Leo C, Giaccia AJ, Denko NC. The hypoxic tumor microenvironment and gene expression. Semin Radiat Oncol. 2004;14:207–14.PubMedCrossRef
69.
Harrison L, Blackwell K. Hypoxia and anemia: factors in decreased sensitivity to radiation therapy and chemotherapy? Oncologist. 2004;9(Suppl 5):31–40.PubMedCrossRef
70.
Richards T, Baikady RR, Clevenger B, Butcher A, Abeysiri S, Chau M, et al. Preoperative intravenous iron for anaemia in elective major open abdominal surgery: the PREVENTT RCT. Health Technol Assess. 2021;25:1–58.PubMedPubMedCentralCrossRef
71.
Keeler BD, Dickson EA, Simpson JA, Ng O, Padmanabhan H, Brookes MJ, et al. The impact of pre-operative intravenous iron on quality of life after colorectal cancer surgery: outcomes from the intravenous iron in colorectal cancer-associated anaemia (IVICA) trial. Anaesthesia. 2019;74:714–25.PubMedCrossRef
72.
• Pang Q-Y, An R, Liu H-L. Perioperative transfusion and the prognosis of colorectal cancer surgery: a systematic review and meta-analysis. World J Surg Oncol. 2019;17:7. This meta-analysis of observational studies found that perioperative transfusion results in a significantly negative effect on long-term prognosis and increases short-term complications after colorectal cancer surgery.PubMedPubMedCentralCrossRef
73.
Deeb A-P, Aquina CT, Monson JRT, Blumberg N, Becerra AZ, Fleming FJ. Allogeneic leukocyte-reduced red blood cell transfusion is associated with postoperative infectious complications and cancer recurrence after colon cancer resection. Dig Surg. 2020;37:163–70.PubMedCrossRef
74.
Petrelli F, Ghidini M, Ghidini A, Sgroi G, Vavassori I, Petrò D, et al. Red blood cell transfusions and the survival in patients with cancer undergoing curative surgery: a systematic review and meta-analysis. Surg Today. 2021;51:1535–57.PubMedCrossRef
75.
Velásquez JF, Cata JP. Transfusions of blood products and cancer outcomes. Rev Esp Anestesiol Reanim. 2015;62:461–7.PubMedCrossRef
76.
Ma X, Liu Y, Han Q, Han Y, Wang J, Zhang H. Transfusion‑related immunomodulation in patients with cancer: Focus on the impact of extracellular vesicles from stored red blood cells (Review). Int J Oncol. 2021;59(6):108. 
77.
Myles PS, Bellomo R, Corcoran T, Forbes A, Peyton P, Story D, et al. Restrictive versus liberal fluid therapy for major abdominal surgery. N Engl J Med. 2018;378:2263–74.PubMedCrossRef
78.
• Zorrilla-Vaca A, Ripolles-Melchor J, Fernandez-Valdes P, Ruiz-Escobar A. Association of liberal fluid therapy for colorectal cancer surgery and long-term oncologic recurrence. Ann Surg Oncol. 2022;29:1523–1525. This study showed that in patients undergoing elective colorectal surgery, liberal fluid therapy was associated with worse oncologic outcomes at 5-year follow-up.
79.
Diaper J, Schiffer E, Barcelos GK, Luise S, Schorer R, Ellenberger C, et al. Goal-directed hemodynamic therapy versus restrictive normovolemic therapy in major open abdominal surgery: a randomized controlled trial. Surgery. 2021;169:1164–74.PubMedCrossRef
80.
Ripollés-Melchor J, Chappell D, Espinosa, Mhyten MG, Abad-Gurumeta A, Bergese SD, et al. Perioperative fluid therapy recommendations for major abdominal surgery. Via RICA recommendations revisited. Part I: Physiological background. Rev Esp Anestesiol Reanim. 2017;64:328–38.
81.
Beilin B, Shavit Y, Razumovsky J, Wolloch Y, Zeidel A, Bessler H. Effects of mild perioperative hypothermia on cellular immune responses. Anesthesiology. 1998;89:1133–40.PubMedCrossRef
82.
Kurz A, Sessler DI, Lenhardt R. Perioperative normothermia to reduce the incidence of surgical-wound infection and shorten hospitalization. Study of Wound Infection and Temperature Group. N Engl J Med. 1996;334:1209–15.PubMedCrossRef
83.
Gottschalk A, Sharma S, Ford J, Durieux ME, Tiouririne M. Review article: the role of the perioperative period in recurrence after cancer surgery. Anesth Analg. 2010 Jun;110:1636–43.PubMedCrossRef
84.
Mortensen K, Nilsson M, Slim K, Schäfer M, Mariette C, Braga M, et al. Consensus guidelines for enhanced recovery after gastrectomy: Enhanced Recovery After Surgery (ERAS®) Society recommendations. Br J Surg. 2014;101:1209–29.PubMedCrossRef
85.
Gustafsson UO, Scott MJ, Schwenk W, Demartines N, Roulin D, Francis N, et al. Guidelines for perioperative care in elective colonic surgery: Enhanced recovery after surgery (ERAS®) society recommendations. Clin Nutr. 2012;31:783–800.PubMedCrossRef
86.
Chang C-Y, Wu M-Y, Chien Y-J, Su I-M, Wang S-C, Kao M-C. Anesthesia and long-term oncological outcomes: a systematic review and meta-analysis. Anesth Analg. 2021;132:623–34.PubMedCrossRef
87.
•• Makito K, Matsui H, Fushimi K, Yasunaga H. Volatile versus total intravenous anesthesia for cancer prognosis in patients having digestive cancer surgery. Anesthesiology. 2020;133:764–73. A study of more than 200,000 patients found that oncologic outcomes at 5-year follow-up were not different depending on the type of anesthetic used.PubMedCrossRef
88.
Dobson GP. Addressing the global burden of trauma in major surgery. Front Surg. 2015;2:1–26.CrossRef
89.
Zhang J, Yao N, Tian S. Morphine stimulates migration and growth and alleviates the effects of chemo drugs via AMPK-dependent induction of epithelial-mesenchymal transition in esophageal carcinoma cells. Biol Pharm Bull. 2020;43:774–81.PubMedCrossRef
90.
Gaspani L, Bianchi M, Limiroli E, Panerai AE, Sacerdote P. The analgesic drug tramadol prevents the effect of surgery on natural killer cell activity and metastatic colonization in rats. J Neuroimmunol. 2002;129:18–24.PubMedCrossRef
91.
Özgürbüz U, Gencür S, Kurt FÖ, Özkalkanlı M, Vatansever HS. The effects of tramadol on cancer stem cells and metabolic changes in colon carcinoma cells lines. Gene. 2019;718:144030.PubMedCrossRef
92.
Rangel FP, Auler JOC, Carmona MJC, Cordeiro MD, Nahas WC, Coelho RF, et al. Opioids and premature biochemical recurrence of prostate cancer: a randomised prospective clinical trial. Br J Anaesth. 2021;126:931–9.PubMedCrossRef
93.
Silagy AW, Hannum ML, Mano R, Attalla K, Scarpa JR, DiNatale RG, et al. Impact of intraoperative opioid and adjunct analgesic use on renal cell carcinoma recurrence: role for onco-anaesthesia. Br J Anaesth. 2020;125:e402–4.PubMedPubMedCentralCrossRef
94.
Du KN, Feng L, Newhouse A, Mehta J, Lasala J, Mena GE, et al. Effects of intraoperative opioid use on recurrence-free and overall survival in patients with esophageal adenocarcinoma and squamous cell carcinoma. Anesth Analg. 2018;127(1):210–6.
95.
Sessler DI, Pei L, Huang Y, Fleischmann E, Marhofer P, Kurz A, et al. Recurrence of breast cancer after regional or general anaesthesia: a randomised controlled trial. Lancet. 2019;394:1807–15.PubMedCrossRef
96.
Falk W, Magnuson A, Eintrei C, Henningsson R, Myrelid P, Matthiessen P, et al. Comparison between epidural and intravenous analgesia effects on disease-free survival after colorectal cancer surgery: a randomised multicentre controlled trial. Br J Anaesth. 2021;127:65–74.PubMedPubMedCentralCrossRef
97.
Kranke P, Jokinen J, Pace NL, Schnabel A, Hollmann MW, Hahnenkamp K, Eberhart LH, Poepping DM, Weibel S. Continuous intravenous perioperative lidocaine infusion for postoperative pain and recovery. Cochrane Database Syst Rev. 2015; (7):CD009642.
98.
99.
López M, Padilla ML, García B, Orozco J, Rodilla AM. Prevention of acute postoperative pain in breast cancer: a comparison between opioids versus ketamine in the intraoperatory analgesia. Pain Res Manag. 2021;2021:1–8.CrossRef
100.
Cho JS, Kim NY, Shim JK, Jun JH, Lee S, Kwak YL. The immunomodulatory effect of ketamine in colorectal cancer surgery: a randomized-controlled trial. Can J Anaesth. 2021;68:683–92.PubMedCrossRef
101.
Volta CA, Alvisi V, Campi M, Marangoni E, Alvisi R, Castellazzi M, et al. Influence of different strategies of volume replacement on the activity of matrix metalloproteinases: an in vitro and in vivo study. Anesthesiology. 2007;106:85–91.PubMedCrossRef
102.
Connolly JG, Tan KS, Mastrogiacomo B, Dycoco J, Caso R, Jones GD, et al. Intraoperative opioid exposure, tumour genomic alterations, and survival differences in people with lung adenocarcinoma. Br J Anaesth [Internet]. 2021;127:75–84.CrossRef
103.
Chen HY, Li GH, Tan GC, Liang H, Lai XH, Huang Q, et al. Dexmedetomidine enhances hypoxia-induced cancer cell progression. Exp Ther Med. 2019;18:4820.PubMedPubMedCentral
104.
Lavon H, Matzner P, Benbenishty A, Sorski L, Rossene E, Haldar R, et al. Dexmedetomidine promotes metastasis in rodent models of breast, lung, and colon cancers. Br J Anaesth. 2018;120:188–96.PubMedCrossRef
105.
Newhook TE, Soliz JM, Prakash LR, Hancher-Hodges S, Speer BB, Wilks JA, et al. Impact of intraoperative dexamethasone on surgical and oncologic outcomes for patients with resected pancreatic ductal adenocarcinoma. Ann Surg Oncol. 2021;28:1563–9.PubMedCrossRef
106.
Kim MH, Kim DW, Park S, Kim JH, Lee KY, Hwang J, et al. Single dose of dexamethasone is not associated with postoperative recurrence and mortality in breast cancer patients: a propensity-matched cohort study. BMC Cancer. 2019;20(19):251.CrossRef
107.
Yu HC, Luo YX, Peng H, Kang L, Huang MJ, Wang JP. Avoiding perioperative dexamethasone may improve the outcome of patients with rectal cancer. Eur J Surg Oncol. 2015;41:667–73.PubMedCrossRef
Metadaten
Titel
Enhanced Recovery After Surgery (ERAS) in Surgical Oncology
verfasst von
Javier Ripollés-Melchor
Ane Abad-Motos
Andrés Zorrilla-Vaca
Publikationsdatum
11.04.2022
Verlag
Springer US
Erschienen in
Current Oncology Reports / Ausgabe 9/2022
Print ISSN: 1523-3790
Elektronische ISSN: 1534-6269
DOI
https://doi.org/10.1007/s11912-022-01282-4

Weitere Artikel der Ausgabe 9/2022

Current Oncology Reports 9/2022 Zur Ausgabe

Lymphomas (T Hilal, Section Editor)

Quality of Life and Survivorship in Lymphoma

Lymphomas (T Hilal, Section Editor)

Targeting The Tumor Microenvironment in Lymphomas: Emerging Biological Insights and Therapeutic Strategies

Pediatric Oncology (KL Davis, Section Editor)

Current Approaches in Hepatoblastoma—New Biological Insights to Inform Therapy

Head and Neck Cancers (EY Hanna, Section Editor)

Predictors of Nodal Metastasis in Cutaneous Head and Neck Cancers

Head and Neck Cancers (EY Hanna, Section Editor)

Emerging Disparities in Prevention and Survival Outcomes for Patients with Head and Neck Cancer and Recommendations for Health Equity

Cancer Rehabilitation (S Shahpar, Section Editor)

Breast Cancer Survivorship: the Role of Rehabilitation According to the International Classification of Functioning Disability and Health—a Scoping Review

Neu im Fachgebiet Onkologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

13.05.2024 Pankreaskarzinom Nachrichten

Gerade bei aggressiven Malignomen wie dem duktalen Adenokarzinom des Pankreas könnte Früherkennung die Therapiechancen verbessern. Noch jedoch klafft hier eine Lücke. Ein Studienteam hat einen Weg gesucht, sie zu schließen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise